DOCSLIB.ORG

Introduction - Fungal Disease in Britain and the United States 1850–2000 - NCBI Bookshelf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction - Fungal Disease in Britain and the United States 1850–2000 - NCBI Bookshelf 22-4-2020 Introduction - Fungal Disease in Britain and the United States 1850–2000 - NCBI Bookshelf NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Homei A, Worboys M. Fungal Disease in Britain and the United States 1850–2000: Mycoses and Modernity. Basingstoke (UK): Palgrave Macmillan; 2013. Introduction Fungal infections or mycoses are the great neglected diseases of medical history.1 There are numerous histories of viral, bacterial and protozoan infections, for all times and all places, but very few studies of those caused by fungi. Why? It cannot be because of prevalence. Historical sources and contemporary epidemiological investigations show that fungal infections were and are ubiquitous in human and animal populations. Everyone in Britain and the United States in the last half a century would have heard of, if not suffered from, athlete’s foot or thrush. In the first half of the twentieth century, children feared the school nurse finding ringworm on their scalp and having to endure, not only the pains of X-ray depilation or having their shaven head painted with gentian violet, but also exclusion from school and the shame of being stigmatised as ‘unclean’.2 It seems that medical historians have followed the agenda of the medical profession in showing relatively little interest in conditions, such as the majority of cases of mycoses, that do not lead to ‘illness’ as such, but cause inflammation, irritation and discomfort. Medical history remains dominated by studies of diseases that had, or continue to have, a high profile within medicine, or have attracted government interest and investment because they cause significant morbidity or mortality. Yet, the majority experience of ill health was, and is, of self-limiting and self- treated conditions, where sufferers did not, and do not, consult a doctor and become ‘patients’. In their efforts to recover ‘the patient’s view’, medical historians have ignored the minor illnesses, injuries and infections that were, and remain, outside of the medical gaze.3 But medical historians have also largely ignored the ailments brought on by medical advances, and here too the history of fungal infections can be instructive. The grand narrative of Western medicine in the twentieth century was one of ‘progress’, evidenced by greater, scientifically based knowledge of the aetiology and pathology of disease, more accurate diagnostics, improved management of symptoms and pain, more effective treatments, innovations in surgery, improved health care, falling mortality rates and greater longevity.4 Those telling this story recognised that progress was not unalloyed, yet amongst doctors such was the step change in their effectiveness and efficiency that problems, like the development of antibiotic resistance, were discounted or seen as something that would be solved by further scientific and technological advances.5 However, medical professionals soon realised that therapeutic and technological advances often led to intractable problems; for example, the practice of managing the adverse effects of one drug with another could lead to patients taking more medicines to manage side effects than for their primary illness. Such practices were criticised in the 1960s, but for our narrative of fungal infections Ivan Illich’s book Medical Nemesis, first published in 1975, is most relevant.6 Illich made iatrogenesis – doctor induced disease – central to his critique of modern medicine, claiming that around 10% of all clinical encounters were for such conditions. He argued that the cures of modern medicine were often worse than the disease – if indeed there was a disease in the first place, as Illich also attacked the medicalisation of everyday life, anticipating the burgeoning of risk-defined conditions that emerged in the last quarter of the twentieth century.7 Thrush, the most prevalent opportunistic mycosis of the twentieth century, exemplifies these trends. In the 1940s and 1950s, the emergence of resistant bacteria was only one side effect of the new drugs. More important then was the development of so-called ‘superinfections’, also caused by antibiotics as they removed not just disease-causing bacteria but many others, and altered the normal microbial flora of the body. These changes opened the body to opportunistic infection by other bacteria, such as Staphylococcus aureus, and by fungi, especially Candida. This fungus had previously only affected the ‘external’ mucus membranes in the mouth and genitalia, but emerged in the 1950s as a rare, but serious, internal and systemic infection, where fungi grew on major organs, such as the heart. It was not just patients on antibiotics who were vulnerable. There were a growing number of patients whose immune systems were weakened or immunocompromised. Initially, this situation developed as a side effect of steroids and other similar treatments, but then such states were deliberately produced by doctors to aid the acceptance of transplanted organs, or as a by-product of new cancer therapies. In 1987, John W. Rippon, a leading American medical mycologist, reflected on the situation. https://www.ncbi.nlm.nih.gov/books/NBK169219/?report=printable 1/10 22-4-2020 Introduction - Fungal Disease in Britain and the United States 1850–2000 - NCBI Bookshelf The mycology of human infections in the 1980s is the mycology of the soil, rotting vegetables, shower curtains, toilet bowls, leaf piles, wilted flowers and dung heaps. Organisms literally come out of the walls to infect immunosuppressed patients. Technical medical and surgical expertise is such that we can pass around hearts, lungs, and livers only to be thwarted by a Fusarium from a rotting plum.8 Rippon was pointing to a larger truth about human fungal infections, namely, that their prevalence has been linked to specific ecological conditions and interactions, not only within the body, but also within the wider social and physical environment. At the time Rippon wrote, the United States, and soon the Western world, was gripped by a popular health panic about fungal disease. Some fringe doctors promoted the view that Candida infection was responsible for all manner of ‘modern’ ailments, including chronic fatigue syndrome (CFS) and inflammatory bowel disease (IBD), in what they styled as ‘the yeast connection’.9 In this book, we discuss the changing medical and public profile of fungal infections in the period 1850–2000. We consider four sets of diseases: ringworm and athlete’s foot (dermatophytosis); thrush or candidiasis (infection with Candida albicans); endemic, geographically specific infections in North America (coccidioidomycosis, blastomycosis and histoplasmosis) and mycotoxins; and aspergillosis (infection with Aspergillus fumigatus). We discuss each disease in relation to developing medical knowledge and practices, and to social changes associated with ‘modernity’. Thus, mass schooling provided ideal conditions for the spread of ringworm of the scalp in children, and the rise of college sports and improvement of personal hygiene led to the spread of athlete’s foot. Antibiotics seemed to open the body to more serious Candida infections, as did new methods to treat cancers and the development of transplantation. Regional fungal infections in North America came to the fore due to the economic development of certain regions, where population movement brought in non-immune groups who were vulnerable to endemic mycoses. Fungal toxins or mycotoxins were discovered as by-products of modern food storage and distribution technologies. Lastly, the rapid development and deployment of new medical technologies, such as intensive care and immunosuppression in the last quarter of the twentieth century, increased the incidence of aspergillosis and other systemic mycoses. In understanding and managing infectious diseases, scientists and doctors have long argued for thinking about them in terms of the metaphor of ‘seed and soil’, where the ‘seed’ is the infectious organism or pathogen: that is, virus, bacteria, fungi, protozoa (single cell) or metazoan (multicellular); and the ‘soil’ is the human body and its environs.10 Thus, for someone with the common cold, the notion of ‘seed and soil’ ensures that we go beyond focusing only on infection by the virus (the seed) and consider the sufferer (the soil). This means looking at the conditions in which the person was exposed to the virus, the quantity and quality of the virus reaching the body, the nature of the body’s specific immune response and the overall health of the individual. We all know that we do not ‘catch a cold’ every time we are exposed to the virus and that some people suffer longer and more serious illness than others do. Some variations are individual, but epidemiological studies have always shown patterns of exposure, susceptibility, sickness and recovery by age, gender, class, occupation, ethnicity and other socio-cultural variables. For example, in their history of pulmonary tuberculosis, René and Jean Dubos systematically use the notion of ‘seed and soil’ to discuss the disease at all levels, from biological factors influencing the susceptibility of cells and tissues, through to the socio- economic and technological variables that have shaped global trends in morbidity and mortality.11 In this book, we frame our history of fungal infections in terms of ‘seed and soil’; hence, our ‘seeds’ are specific fungal pathogens and we interpret ‘soils’ widely to include the human body, social relations and structures, and the medical, material and technological environment. Fungi Fungi and how they cause diseases are not well known, so it will be useful here to give a brief introduction to the nature of the ‘seeds’ of mycoses. Our account is part historical and part current. Mycology is the branch of science that studies fungi and until the 1960s, it was a part of botany, at which time its subject matter was moved to the animal kingdom. Since then, fungi have been placed in their own kingdom, with the other four being plants, animals, protozoa and monera (bacteria).12 Current estimates are that there are well over 100,000 species of fungi and many more are still to be classified, let alone discovered.
Load more

Recommended publications
  • Introduction
    Notes Introduction 1. In the book, we use the terms ‘fungal infections’ and ‘mycoses’ (or singular fungal infection and mycosis) interchangeably, mostly following the usage of our historical actors in time and place. 2. The term ‘ringworm’ is very old and came from the circular patches of peeled, inflamed skin that characterised the infection. In medicine at least, no one understood it to be associated with worms of any description. 3. Porter, R., ‘The patient’s view: Doing medical history from below’, Theory and Society, 1985, 14: 175–198; Condrau, F., ‘The patient’s view meets the clinical gaze’, Social History of Medicine, 2007, 20: 525–540. 4. Burnham, J. C., ‘American medicine’s golden age: What happened to it?’, Sci- ence, 1982, 215: 1474–1479; Brandt, A. M. and Gardner, M., ‘The golden age of medicine’, in Cooter, R. and Pickstone, J. V., eds, Medicine in the Twentieth Century, Amsterdam, Harwood, 2000, 21–38. 5. The Oxford English Dictionary states that the first use of ‘side-effect’ was in 1939, in H. N. G. Wright and M. L. Montag’s textbook: Materia Med Pharma- col & Therapeutics, 112, when it referred to ‘The effects which are not desired in any particular case are referred to as “side effects” or “side actions” and, in some instances, these may be so powerful as to limit seriously the therapeutic usefulness of the drug.’ 6. Illich, I., Medical Nemesis: The Expropriation of Health, London, Calder & Boyars, 1975. 7. Beck, U., Risk Society: Towards a New Society, New Delhi, Sage, 1992, 56 and 63; Greene, J., Prescribing by Numbers: Drugs and the Definition of Dis- ease, Baltimore, Johns Hopkins University Press, 2007; Timmermann, C., ‘To treat or not to treat: Drug research and the changing nature of essential hypertension’, Schlich, T.
    [Show full text]
  • Cidara-IFI-Infogr-12.Pdf
    ­­ ­ ­ We often think of fungal infections as simply bothersome conditions such as athlete’s foot or toenail fungus. But certain types of fungal infections, known as “ ”( ), can be dangerous and fatal. IFIs are systemic and are typically caused when fungi invade the body in various ways such as through the bloodstream or by the inhalation of spores. IFIs can also spread to many other organs such as the liver and kidney. They are associated with ­ ( ) > % ­ • Invasive candidiasis ( ) is a ­ common hospital-acquired infection in the U.S., % cases each year.v • Invasive aspergillosis () occurs most often in people with weakened immune systems or lung disease, and its prevalence is vi ­ An increasing number of people in the U.S. have putting them at greater risk for IFIs.x High-risk groups include: hospitalized patients cancer or transplant patients patients undergoing surgery patients with chronic diseases Rates of invasive candidiasis are dicult ( )is an emerging drug-resistant to estimate and can vary based on time, fungus that spreads quickly and has caused serious region, and study type. and deadly infections in over a dozen countries. + Still, it is clear that overall The CDC estimates that remain high – especially in the U.S. with invasive ix among viii ­ There is an increasingly urgent need to develop new therapies for IFIs, ­ Currently available treatments for IFIs have signicant limitations such as: • toxicities/side eects • inconsistent achievement of target drug levels • interactions with other drugs • increasing microbial resistance As the urgency around IFIs rises, multiple biopharma companies and researchers are working to develop new therapies to treat and prevent them.
    [Show full text]
  • Oral Candidiasis: a Review
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Issue 4, 2010 Review Article ORAL CANDIDIASIS: A REVIEW YUVRAJ SINGH DANGI1, MURARI LAL SONI1, KAMTA PRASAD NAMDEO1 Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur (C.G.) – 49500 Email: [email protected] Received: 13 Jun 2010, Revised and Accepted: 16 July 2010 ABSTRACT Candidiasis, a common opportunistic fungal infection of the oral cavity, may be a cause of discomfort in dental patients. The article reviews common clinical types of candidiasis, its diagnosis current treatment modalities with emphasis on the role of prevention of recurrence in the susceptible dental patient. The dental hygienist can play an important role in education of patients to prevent recurrence. The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at‐risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non‐albicans Candida, non‐fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Oral candidiasis is a common fungal infection in patients with an impaired immune system, such as those undergoing chemotherapy for cancer and patients with AIDS. It has a high morbidity amongst the latter group with approximately 85% of patients being infected at some point during the course of their illness. A major predisposing factor in HIV‐infected patients is a decreased CD4 T‐cell count.
    [Show full text]
  • Candida Auris
    microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks.
    [Show full text]
  • Oral Antifungals Month/Year of Review: July 2015 Date of Last
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
    [Show full text]
  • Fungal Infections – an Overview
    REVIEW Fungal infections – An overview Natalie Schellack, BCur, BPharm, PhD(Pharmacy); Jade du Toit, BPharm; Tumelo Mokoena, BPharm; Elmien Bronkhorst, BPharm, MSc(Med) School of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University Correspondence to: Prof Natalie Schellack, [email protected] Abstract Fungi normally originate from the environment that surrounds us, and appear to be harmless until inhaled or ingestion of spores occurs. A pathogenic fungus may lead to infection. People who are at risk of acquiring fungal infection are those living with human immunodeficiency virus (HIV), cancer, receiving immunosuppressant therapy, neonates and those of advanced age. The management of superficial fungal infections is mainly topical, with agents including terbinafine, miconazole and ketoconazole. Oral treatment includes griseofulvin and fluconazole. Invasive fungal infections are difficult to treat, and are managed with agents including the azoles, echinocandins and amphotericin B. This paper provides a general overview of the management of fungus infections. © Medpharm S Afr Pharm J 2019;86(1):33-40 Introduction more advanced biochemical or molecular testing.4 Fungi normally originate from the environment that surrounds Superficial fungal infections us, and appear to be harmless until inhaled or ingestion of spores Either yeasts or fungi can cause dermatomycosis, or superficial occurs. Infection with fungi is also more likely when the body’s fungal infections.7 Fungi that infect the hair, skin, nails and mucosa immune system becomes weakened. A pathogenic fungus may lead to infection. The number of fungus species ranges in the can cause a superficial fungal infection. Dermatophytes are found millions and only a few species seem to be harmful to humans; the naturally in soil, human skin and keratin-containing structures, 3 ones found mostly on the mucous membrane and the skin have which provide them with a source of nutrition.
    [Show full text]
  • Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
    Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting a b,c, Alexander Lepak, MD , David Andes, MD * KEYWORDS Invasive candidiasis Pharmacokinetics-pharmacodynamics Therapy Source control Invasive fungal infections (IFI) and fungal sepsis in the intensive care unit (ICU) are increasing and are associated with considerable morbidity and mortality. In this setting, IFI are predominantly caused by Candida species. Currently, candidemia represents the fourth most common health care–associated blood stream infection.1–3 With increasingly immunocompromised patient populations, other fungal species such as Aspergillus species, Pneumocystis jiroveci, Cryptococcus, Zygomycetes, Fusarium species, and Scedosporium species have emerged.4–9 However, this review focuses on invasive candidiasis (IC). Multiple retrospective studies have examined the crude mortality in patients with candidemia and identified rates ranging from 46% to 75%.3 In many instances, this is partly caused by severe underlying comorbidities. Carefully matched, retrospective cohort studies have been undertaken to estimate mortality attributable to candidemia and report rates ranging from 10% to 49%.10–15 Resource use associated with this infection is also significant. Estimates from numerous studies suggest the added hospital cost is as much as $40,000 per case.10–12,16–20 Overall attributable costs are difficult to calculate with precision, but have been estimated to be close to 1 billion dollars in the United States annually.21 a University of Wisconsin, MFCB, Room 5218, 1685 Highland Avenue, Madison, WI 53705-2281, USA b Department of Medicine, University of Wisconsin, MFCB, Room 5211, 1685 Highland Avenue, Madison, WI 53705-2281, USA c Department of Microbiology and Immunology, University of Wisconsin, MFCB, Room 5211, 1685 Highland Avenue, Madison, WI 53705-2281, USA * Corresponding author.
    [Show full text]
  • Up to Date Epidemiology, Diagnosis and Management of Invasive Fungal Infections
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector EDITORIAL 10.1111/1469-0691.12642 Up to date epidemiology, diagnosis and management of invasive fungal infections I. Oren and M. Paul Infectious Diseases Institute, Rambam Health Care Campus, Bruce Rappaport Faculty of Medicine, Technion – Israely Institute of Technology, Haifa, Israel E-mail: [email protected] This issue of Clinical Microbiology and Infection is dedicated to and the presence of GVHD. However, the incidence of invasive fungal infections (IFI) based on the ESCMID confer- invasive aspergillosis is very much dependent on local epide- ence held in Rome on January 2013. The reviews summarize miology and the quality of air control in hemato-oncological the progress achieved in the fields of epidemiology, diagnosis units. Thus, in some settings, invasive aspergillosis is more and management of Candida, Aspergillus and Mucor invasive frequent than invasive candidiasis [2]. infections. Mucormycosis is the second most common invasive mould infection and its incidence increased from 0.7 per million in 1997 to 1.2 per million in 2006 [3]. In addition to immune- Epidemiology suppression, there are some unique host risk factors for mucormycosis such as diabetes keto-acidosis, burns, iron Candida spp. have become important causes of sepsis in overload and, on the other hand, deferoxamine therapy. The hospitals with incidence constantly growing over the last specific clinical syndrome of mucormycosis is associated with 20 years. Candida spp. is now the 4th most common isolate of host risk factors; thus, pulmonary mucormycosis is more bloodstream infections in many countries (and the most common in patients with hematological malignancies, while common IFI), mainly due to the increasing complexity of rhino-cerebral mucormycosis is more common in diabetic medical care [1].
    [Show full text]
  • Candida Albicans
    Zhang et al. BMC Infectious Diseases (2020) 20:126 https://doi.org/10.1186/s12879-020-4856-8 CASE REPORT Open Access Molecular mechanism of azoles resistant Candida albicans in a patient with chronic mucocutaneous candidiasis Ming-rui Zhang1, Fei Zhao2, Shuang Wang1, Sha Lv1, Yan Mou1, Chun-li Yao1, Ying Zhou1 and Fu-qiu Li1* Abstract Background: More and more azole-resistant strains emerged through the development of acquired resistance and an epidemiological shift towards inherently less susceptible species. The mechanisms of azoles resistance of Candida albicans is very complicated. In this study, we aim to investigate the mechanism of azole-resistant C. albicans isolated from the oral cavity of a patient with chronic mucocutaneous candidiasis (CMC). Case presentation: CMC diagnosis was given based on clinical manifestations, laboratory test findings and gene sequencing technique. Minimum inhibitory concentration (MIC) of the fungal isolate, obtained from oral cavity termed as CA-R, was obtained by in vitro anti-fungal drugs susceptibility test. To further investigate the resistant mechanisms, we verified the mutations of drug target genes (i.e. ERG11 and ERG3) by Sanger sequencing, and verified the over-expression of ERG11 and drug efflux genes (i.e. CDR1 and CDR2) by RT-PCR. A heterozygous mutation of c.1162A > G resulting in p.K388E was detected in STAT1 of the patient. The expression of CDR1 and CDR2 in CA-R was 4.28-fold and 5.25-fold higher than that of type strain SC5314, respectively. Conclusions: Up-regulation of CDR1 and CDR2 was mainly responsible for the resistance of CA-R.
    [Show full text]
  • CDHO Factsheet Oral Candidiasis
    Disease/Medical Condition CANDIDIASIS Date of Publication: May 7, 2014 (also known as “candidosis” and “moniliais”; and “thrush”; usually caused by overgrowth of yeast fungus Candida albicans, but occasionally by other species of Candida) Is the initiation of non-invasive dental hygiene procedures* contra-indicated? No Is medical consult advised? ......................................... Yes, if the candidiasis has not yet been assessed by physician or dentist for definitive diagnosis (clinically or via microscopy of scraping) and management (including potential prescription medication). Is the initiation of invasive dental hygiene procedures contra-indicated?** No Is medical consult advised? ....................................... See above. Is medical clearance required? ................................... No Is antibiotic prophylaxis required? .............................. No Is postponing treatment advised? ................................ Yes, until candidiasis has been treated and is resolved. Oral management implications Mode of transmission is contact with secretions or excretions of mouth, skin, vagina, and feces, from patients/clients or carriers; by passage from mother to baby during childbirth; and by endogenous spread. Babies with oral thrush can pass the infection to their mothers’ nipples during breast-feeding. Because Candida yeasts are normal flora of the human mouth, a positive culture does not necessarily make the diagnosis. Good oral hygiene practices can help prevent oral candidiasis in people with weakened
    [Show full text]
  • Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 May 17. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1791–1797. doi:10.1093/cid/ciy776. Estimation of direct healthcare costs of fungal diseases in the United States Kaitlin Benedict, Brendan R. Jackson, Tom Chiller, and Karlyn D. Beer Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Abstract Background: Fungal diseases range from relatively minor superficial and mucosal infections to severe, life-threatening systemic infections. Delayed diagnosis and treatment can lead to poor patient outcomes and high medical costs. The overall burden of fungal diseases in the United States is challenging to quantify because they are likely substantially underdiagnosed. Methods: To estimate total national direct medical costs associated with fungal diseases from a healthcare payer perspective, we used insurance claims data from the Truven Health MarketScan® 2014 Research Databases, combined with hospital discharge data from the 2014 Healthcare Cost and Utilization Project National Inpatient Sample and outpatient visit data from the 2005–2014 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. All costs were adjusted to 2017 dollars. Results: We estimate that fungal diseases cost more than $7.2 billion in 2017, including $4.5 billion from 75,055 hospitalizations and $2.6 billion from 8,993,230 outpatient visits. Hospitalizations for Candida infections (n=26,735, total cost $1.4 billion) and Aspergillus infections (n=14,820, total cost $1.2 billion) accounted for the highest total hospitalization costs of any disease.
    [Show full text]
  • Introduction
    OPEN Introduction Fungal infections or mycoses are the great neglected diseases of medical history.1 There are numerous histories of viral, bacterial and protozoan infections, for all times and all places, but very few studies of those caused by fungi. Why? It cannot be because of prevalence. Histori- cal sources and contemporary epidemiological investigations show that fungal infections were and are ubiquitous in human and animal popula- tions. Everyone in Britain and the United States in the last half a century would have heard of, if not suffered from, athlete’s foot or thrush. In the first half of the twentieth century, children feared the school nurse find- ing ringworm on their scalp and having to endure, not only the pains of X-ray depilation or having their shaven head painted with gentian vio- let, but also exclusion from school and the shame of being stigmatised as ‘unclean’.2 It seems that medical historians have followed the agenda of the med- ical profession in showing relatively little interest in conditions, such as the majority of cases of mycoses, that do not lead to ‘illness’ as such, but cause inflammation, irritation and discomfort. Medical history remains dominated by studies of diseases that had, or continue to have, a high profile within medicine, or have attracted government interest and investment because they cause significant morbidity or mortality. Yet, the majority experience of ill health was, and is, of self-limiting and self-treated conditions, where sufferers did not, and do not, consult a doctor and become ‘patients’. In their efforts to recover ‘the patient’s view’, medical historians have ignored the minor illnesses, injuries and infections that were, and remain, outside of the medical gaze.3 But medical historians have also largely ignored the ailments brought on by medical advances, and here too the history of fungal infections 1 A.
    [Show full text]